Treatment of KRAS-mutated cancers

JP2024500288A5Inactive Publication Date: 2024-11-27MEI PHARMA INC
0 Cites 0 Cited by

Patent Information

Application Number
JP2023530278
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-04-10
Filing Date
2021-11-19
Publication Date
2024-11-27
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

The disclosure herein provides combination therapy for the treatment of KRAS mutant cancer. The disclosure relates to a CDK inhibitor, such as a CDK inhibitor represented by formula I: or a pharma- ceutically acceptable salt thereof and an additional therapeutic agent, for example, an anti-cancer agent. JPEG2024500288000053.jpg4143
Need to check novelty before this filing date? Find Prior Art